caspofungin acetate
Sponsors
University Of Cologne, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, European Organisation for Research and Treatment of Cancer - EORTC
Conditions
Acute Myeloid LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Phase 2
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
CompletedNCT00082537
Start: 2004-04-30End: 2006-10-31Updated: 2017-02-23
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
CompletedNCT00082524
Start: 2004-04-30End: 2007-07-31Updated: 2017-02-23
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
CompletedNCT00110045
Start: 2005-02-28Updated: 2012-09-24
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
TerminatedNCT00238355
Start: 2003-08-31End: 2008-06-30Updated: 2025-04-27
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
CompletedNCT00292071
Start: 2004-05-31End: 2006-07-31Updated: 2017-02-23
Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
CompletedNCT00330395
Start: 2006-05-31End: 2006-10-31Updated: 2017-02-23
Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)
TerminatedNCT01045798
Start: 2010-12-31End: 2012-04-30Updated: 2017-03-24
Phase 3
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
CompletedNCT00008359
Start: 2000-08-31Updated: 2013-01-18
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
CompletedNCT00250432
Start: 2006-01-31End: 2008-03-31Updated: 2017-03-24
A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)
CompletedNCT00379964
Start: 2005-06-30End: 2006-05-31Updated: 2017-02-23
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
CompletedNCT00635648
Start: 2008-01-31End: 2011-05-31Updated: 2017-03-24
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
CompletedNCT00717860
Start: 2008-08-31End: 2010-07-31Updated: 2017-03-23
Empirical Versus Preemptive Antifungal Therapy
CompletedNCT01288378
Start: 2012-03-31End: 2019-04-04Updated: 2023-12-11
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
CompletedNCT01307579
Start: 2011-04-04End: 2020-06-30Updated: 2021-03-30
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
CompletedNCT01503515
Start: 2013-03-21End: 2021-09-30Updated: 2024-10-16
Phase 4
To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation
Not yet recruitingNCT04728971
Start: 2022-10-01End: 2026-02-01Target: 200Updated: 2022-08-16
A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial
Not yet recruitingCTIS2026-525640-14-00
Target: 420Updated: 2026-05-28